Jane Street Group LLC Has $1.47 Million Stock Position in OraSure Technologies, Inc. (NASDAQ:OSUR)

Jane Street Group LLC boosted its stake in shares of OraSure Technologies, Inc. (NASDAQ:OSUR) by 37.3% during the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 406,766 shares of the medical instruments supplier’s stock after buying an additional 110,572 shares during the period. Jane Street Group LLC owned approximately 0.55% of OraSure Technologies worth $1,468,000 as of its most recent filing with the SEC.

Other hedge funds have also recently bought and sold shares of the company. Tower Research Capital LLC TRC grew its stake in shares of OraSure Technologies by 202.3% in the fourth quarter. Tower Research Capital LLC TRC now owns 7,821 shares of the medical instruments supplier’s stock valued at $28,000 after buying an additional 5,234 shares in the last quarter. Causeway Capital Management LLC bought a new position in shares of OraSure Technologies in the fourth quarter valued at $36,000. Raymond James Financial Inc. bought a new position in OraSure Technologies during the fourth quarter worth $37,000. Boothbay Fund Management LLC bought a new position in OraSure Technologies during the fourth quarter worth $42,000. Finally, AXQ Capital LP bought a new position in OraSure Technologies during the fourth quarter worth $51,000. 93.50% of the stock is currently owned by institutional investors and hedge funds.

OraSure Technologies Stock Performance

OSUR opened at $2.63 on Tuesday. OraSure Technologies, Inc. has a fifty-two week low of $2.36 and a fifty-two week high of $5.08. The company has a market capitalization of $196.72 million, a P/E ratio of 17.53 and a beta of 0.42. The stock has a fifty day moving average of $3.06 and a 200-day moving average of $3.55.

OraSure Technologies announced that its Board of Directors has authorized a share buyback program on Monday, March 24th that permits the company to buyback $40.00 million in shares. This buyback authorization permits the medical instruments supplier to reacquire up to 15.6% of its shares through open market purchases. Shares buyback programs are generally an indication that the company’s management believes its stock is undervalued.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on OSUR shares. StockNews.com raised shares of OraSure Technologies from a “sell” rating to a “hold” rating in a research report on Saturday. Evercore ISI reaffirmed an “in-line” rating and set a $3.00 price objective on shares of OraSure Technologies in a research report on Monday.

Insider Transactions at OraSure Technologies

In other news, CFO Kenneth J. Mcgrath bought 64,000 shares of the company’s stock in a transaction dated Thursday, February 27th. The stock was bought at an average price of $3.15 per share, with a total value of $201,600.00. Following the completion of the acquisition, the chief financial officer now owns 371,013 shares of the company’s stock, valued at $1,168,690.95. This represents a 20.85% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Manner Carrie Eglinton acquired 78,625 shares of the business’s stock in a transaction that occurred on Thursday, February 27th. The shares were purchased at an average cost of $3.15 per share, with a total value of $247,668.75. Following the transaction, the chief executive officer now directly owns 1,259,664 shares of the company’s stock, valued at $3,967,941.60. This trade represents a 6.66% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last 90 days, insiders bought 190,284 shares of company stock valued at $600,348. 3.90% of the stock is currently owned by corporate insiders.

OraSure Technologies Profile

OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company’s products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.